BiotechTube

Bupivacaine Liposome Injection

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Local Analgesia Via Infiltration

Conditions

Local Analgesia Via Infiltration

Trial Timeline

May 21, 2024 → Oct 12, 2026

NCT ID
NCT06344091

About Bupivacaine Liposome Injection

Bupivacaine Liposome Injection is a approved stage product being developed by Jiangsu Hengrui Medicine for Local Analgesia Via Infiltration. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06344091. Target conditions include Local Analgesia Via Infiltration.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06344091ApprovedRecruiting

Competing Products

20 competing products in Local Analgesia Via Infiltration

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
Tadalafil + GemcitabineEli LillyPhase 1
33
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + RilvegostomigDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
zolbetuximabAstellas PharmaPre-clinical
23
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
enfortumab vedotin (EV)Astellas PharmaPre-clinical
23
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
Garsorasib, Benmelstobart, Anlotinib + Benmelstobart, Anlotinib + Garsorasib, Cetuximab Beta InjectionSun PharmaceuticalPhase 2
52
ASP3082Astellas PharmaPhase 2
52
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
ASP1948Astellas PharmaPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85